Biotest AG: Biotest AG shareholders accept voluntary public tender offer by CREAT Group
News: Biotest AG / Key word(s): Offer
Dreieich, 14 June, 2017. The shareholders of Biotest AG have accepted the voluntary public tender offer by Tiancheng (Germany) Pharmaceutical Holdings AG, the bidding company controlled by CREAT Group, by fulfilling the minimum acceptance condition of 75 percent of Biotest ordinary shares outstanding. This represents a major step in the successful completion of this transaction. The final completion of the transaction is still subject to merger control in Turkey as well as regulatory approvals.
Dr. Bernhard Ehmer, CEO of Biotest AG: "We are pleased that our shareholders have accepted this offer from CREAT Group. We now have a strong partner that will strengthen our Biotest Next Level strategy and support investments in the development of new products and the expansion of our international presence."
According to the German Securities Acquisition and Takeover Act (WpÜG), shareholders of Biotest AG who have not tendered their shares can still accept the offer by tendering their shares during the additional acceptance period, which is expected to begin on 22 June, 2017 and will end on 5 July, 2017 at midnight CET (24:00 CET).
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|